The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis

Clinical Rheumatology

Volumn 33, Issue 12, 2014, Pages 1823-1827

  Conway, Richard ^a   Doran, Michele F ^a   O’Shea, Finbar D ^a   Crowley, Brendan ^a   Cunnane, Gaye ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Disease modifying antirheumatic drugs; Immunosuppressive Agents; Rheumatoid Arthritis; Screening; Viral hepatitis

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; GOLIMUMAB; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL RECORD; MEDICAL SOCIETY; MIDDLE AGED; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCREENING TEST; TEACHING; ARTHRITIS, RHEUMATOID; BLOOD; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; INFLAMMATION; MASS SCREENING; PROCEDURES; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MASS SCREENING; METHOTREXATE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84937965070     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2612-4     Document Type: Article

References (14)

1. Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989
2. Weinbaum CM, Williams I, Mast EE et al (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1–20
3. Winthrop KL, Calabrese LH (2011) Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70:1701–1703
4. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639
5. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
6. Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B infection. J Hepatol 46:160–170
7. Lan JL, Chen YM, Hsieh TY et al (2011) Kinetics of viral loads and risk of HBV reactivation in HBcAb positive RA patients undergoing anti-TNF-α therapy. Ann Rheum Dis 70:1719–1725
8. Urata Y, Uesato R, Tanaka D et al (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21:16–23
9. Nardone A, Anastassopoulou CG, Theeten H et al (2009) A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 137:961–969
10. Thornton L, Murphy N, Jones L et al (2012) Determination of the burden of hepatitis C virus infection in Ireland. Epidemiol Infect 140:1461–1468
11. IOM (Institute of Medicine) (2010) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. The National Academies Press, Washington, DC
12. Balogun MA, Ramsay ME, Hesketh LM et al (2002) The prevalence of hepatitis C in England and Wales. J Infect 45:219–226
13. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E (1999) The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 122:133–138
14. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352–1355